Magazine article from our research archive:
|
|
US pharma major Bristol-Myers Squibb is acquiring US cancer therapeutics specialist Kosan Biosciences, of Hayward, California, for $190m, gaining two classes of anticancer agents.(Business Digest)
- Article from:
-
Chemistry and Industry
- Article date:
-
June 23, 2008
- Author:
-
|
Copyright informationCOPYRIGHT 2008 Society of Chemical Industry. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
US pharma major Bristol-Myers Squibb is acquiring US cancer therapeutics specialist Kosan Biosciences, of Hayward, California, for $190m, gaining two classes of anticancer agents: heat shock protein 90 ...
Related newspaper, magazine, and journal articles:
|
BMS/Albany $8m deal.(Albany Molecular Research Inc., Bristol-Myers Squibb...
Chemistry and Industry;
November 7, 2005 ;
66 words
...Albany Molecular Research (New York, US) has signed an $8m licensing agreement with pharma major Bristol-Myers Squibb (BMS) for its biogenic amine re-uptake inhibitors, a new class of agents that increase brain levels of serotonin, norepinephrine...
|
|
|
Merck.(Projects & Technology)
Chemistry and Industry;
November 24, 2008 ;
25 words
...US pharma major Merck is to build a $200m vaccine facility in Carlow, southeast Ireland, according to Medical Laboratory World. Completion is scheduled for 2011.
|
|
|
Pfizer.(Projects & Technology)(Pfizer Inc. is building a facility of...
Chemistry and Industry;
February 25, 2008 ;
43 words
...US pharma major Pfizer is to build a 130m [euro] facility for the development and production of inhaled medication in France, where the company's R&D facility is closing in Amboise in March 2008. Construction is expected to begin in spring 2008 and will take five years.
|
|
|
Pfizer.(Business digest)(Brief article)
Chemistry and Industry;
August 25, 2008 ;
41 words
...US pharma major Pfizer has been unable to find a buyer for its Little Island plant in Cork, Ireland, with the result that 180 jobs are to be lost at the plant. Pfizer has the same problem with its other Cork plant at Ringaskiddy, where up to 250 jobs are at risk.
|
|
|
UK pharma major GlaxoSmithKline is acquiring US biopharma concern Genelabs...
Chemistry and Industry;
November 10, 2008 ;
39 words
...UK pharma major GlaxoSmithKline is acquiring US biopharma concern Genelabs for $57m to strengthen its development of therapies against hepatitis C virus. Genelabs will join GSK's drug discovery organisation when the deal is concluded by the end of 2008.
|
|
|
UK pharma major AstraZeneca and the Washington University School of...
Chemistry and Industry;
June 23, 2008 ;
42 words
...UK pharma major AstraZeneca and the Washington University School of Medicine in St Louis, US, are to collaborate on the development of new approaches to the diagnosis and treatment of Alzheimer's disease. The research will focus on biomarkers in the brain and spinal fluid.
|
|
|
Wyeth.(Q1 results reported)(Brief article)
Chemistry and Industry;
May 7, 2007 ;
28 words
...US pharma major Wyeth saw Q1 2007 revenues increase 11% to $5.4bn, with double-digit growth in pharmaceuticals, consumer healthcare and animal health. Total net income was $1.25bn.
|
|
|
US pharma major Merck & Co is to collaborate with US-based ARIAD, which is...
Chemistry and Industry;
July 30, 2007 ;
44 words
...US pharma major Merck & Co is to collaborate with US-based ARIAD, which is involved in the discovery of small molecule cell signalling in the treatment of cancer. The collaboration involves ARIAD's AP23573 inhibitor of the mTOR protein, a so-called 'master switch' in cancer cells.
|
|
|
UK pharma major AstraZeneca has signed a research collaboration with...
Chemistry and Industry;
November 24, 2008 ;
38 words
...UK pharma major AstraZeneca has signed a research collaboration with Columbia University Medical Center, New York, US, to examine how the creation of neuronal cells in adults might offer new approaches to the treatment of anxiety and depression.
|
See all results.
Or, try our
Advanced Search.
|